Browse > Article
http://dx.doi.org/10.13048/jkm.21004

Gamitaeeumjowee-Tang for weight loss in diabetic patients: A retrospective chart review  

Lee, A-Reum (Department of Medical Science of Meridian, College of Korean Medicine, Graduate School, Kyung Hee University)
Lee, Da-Yeon (Nubebe Korean Medical Clinic)
Kim, Min-Ji (Nubebe Korean Medical Clinic)
Lee, Hyang-Sook (Department of Medical Science of Meridian, College of Korean Medicine, Graduate School, Kyung Hee University)
Choi, Ka-Hye (Nubebe Korean Medical Clinic)
Kim, Seo-Young (Nubebe Korean Medical Clinic)
Lim, Young-Woo (Nubebe Korean Medical Clinic)
Park, Young-Bae (Nubebe Mibyeong Research Institute)
Publication Information
The Journal of Korean Medicine / v.42, no.1, 2021 , pp. 46-58 More about this Journal
Abstract
Objectives: The purpose of this study is to report weight changes and analyze adverse events in diabetic patients with Gamitaeeumjowee-Tang for weight loss. Methods: A retrospective chart review of weight change and adverse events was performed during the 10-week weight loss program using Gamitaeeumjowee-tang with low-calorie diets for diabetics(n=61). Weight and BMI changes were compared before and after the program and calculated the percentage of people who lost more than 5% of their weight, also identified whether subjects felt satiated or not. Adverse events were evaluated in terms of causality, severity and system-organ classes. Results: After 10-week weight loss program, significant weight loss (5.9±2.32kg, 7.73% reduction from baseline) and BMI reduction (2.9±0.86) were reported (n=61). Those who lost more than 5 percent of their body weight accounted for 88.5%, and also 88.5% of the participants felt full to help control their appetite. In assessing the causality of adverse events, 'Unlikely' was the most common (66%) and in severity evaluations, almost all symptoms were mild. Insomnia was the most frequently reported during the first 8 weeks, and constipation was reported the most afterwards. Conclusions: A combination of Gamitaeeumjowee-tang and low-calorie diets for 10 weeks appears to help weight reduction without serious adverse events in diabetic patients. Future well-designed prospective clinical studies testing the effectiveness and safety of this weight loss program are warranted.
Keywords
Diabetes; Weight loss; Gamitaeeumjowee-tang; Adverse events; BMI;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lee JE, Song YK, Lim HH. Clinical trial of Taeeumjowui-tang (Taiyintiaowei-tang) on obese patients: randomized, double blind, placebo-controlled study. J Orient Rehab Med. 2010;20(4):197-213.
2 Lim SY, Park SW, Joo JH, Kim SR, Kim DJ, Choi WS. The effects of Taeeumjowui-tang (Taiyintiaowei-tang) on obesity in Sasang constitution. J East-West Med. 2012;37(4):109-16.
3 Park SJ, Nahmkoong W, Cheon CH, Park JS, Jang BH, Shin YC, et al. Efficacy and safety of Taeeumjowi-tang in obese Korean adults: a double-blind, randomized, and placebo-controlled pilot trial. Evid-Based Complement Altern Med. 2013;2013:498935.
4 Hwang MJ, Shin HD, Song MY. Literature review of herbal medicines on treatment of obesity since 2000; mainly about Ephedra Herba. J Korean Med Obes Res. 2007;7(1):39-54.
5 Jang IS, Hwang EH. The Need for Clinical Practice Guidelines in Usage of Mahuang in Weight Loss. J Korean Med Obes Res. 2007;(1):23-9.
6 Jo GW, OK JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity-focused on RCT. J Korean Med. 2017;38(3):170-84.   DOI
7 Yoon NR, Yoo YJ, Kim MJ, Kim SY, Lim YW, Lim HH et al. Analysis of Adverse Events in Weight Loss Program in Combination with 'Gamitaeeumjowee-Tang' and Low-Calorie Diet. J Korean Med Obes Res. 2018;18(1):1-9.   DOI
8 Luyster FS, Dunbar-Jacob J. Sleep quality and quality of life in adults with type 2 diabetes. Diabetes Educ. 2011;379:347-55.   DOI
9 Attarian H, Hachul H, Guttuso T, Phillips B. Treatment of chronic insomnia disorder in menopause: Evaluation of literature. Menopause. 2015;22(6):674-84.   DOI
10 Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34:1481-6.   DOI
11 Kim DH, Park SC, Lee JH, Lee HY, Cho MK, Cho JYi, et al. Recent Research Trends in Korean Medicine Treatment of Diabetes Mellitus - Focusing on Domestic Articles from 2008 to 2013 -. Korean J Orient Int Med. 2013;4(3):240-55.
12 Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, et al. Diabetes Intervention Study, Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care. 1991;14: 308-17.   DOI
13 United Kingdom Prospective Diabetes Study (UK-PDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-8.   DOI
14 Chon S, Park CY, Koh GP, Oh SJ, Woo JT, Kim SW et al. The Effect of Orlistat in Obese Patients with Type 2 Diabetes : Benefit on Abdominal Obesity and Glycemic Control. J Korean Med Obes Res. 2004;13(4):281-92.
15 Lee EJ, Kim TN. Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. Korean J Obes. 2016;25(3):121-8.   DOI
16 Jang HC, Choi SH. Characterization of Patients with Type 2 Diabetes according to Body Mass Index: Korea National Health and Nutrition Examination Survey from 2007 to 2011. Endocrinol Metab. 2015;30:514-21.   DOI
17 Kim HJ, Kim JY. Clinical report about the adverse reactions of Taeeumin.Soeumin.Soyangin by Taeeumjowi-tang. Korean J Oriental Physiology & Pathology. 2008;22(6):1600-5.
18 Jain A, Sharmab R, Yadavc N, Chaudhary P, Jainc G, Maanju M. Quality of life and its association with insomnia and clinical variables in type 2 diabetes. J Egypt Public Health Assoc. 2017;92(1):52-9.   DOI
19 Lee JM. Longevity and life preservation in Eastern medicine, Seoul : Haklimsa. 1986;333-8.
20 Basch E, Reeve B, Mitchell S, Clauser S, Minasian L, Dueck A, et al. Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 2014;106(9):244.
21 Christensen P, Bliddal H, Riecke BF, Leeds AR, Astrup A, Christensen R. Comparison of a low-energy diet and a very low-energy diet in sedentary obese individuals: a pragmatic randomized controlled trial. Clin Obes. 2011;1(1):31-4.   DOI
22 Hwa Kim. Diagnosis and Management of Diabetic Autonomic Neuropathy Chong. J Korean Diabetes. 2018;19:160-7.   DOI
23 National Cancer Institute. National Institute of Health. U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2010.
24 Korea Institute of Drug Safety & Risk Management. Terminology Guide for Reporting Adverse Drug Reactions. Seoul : Korea Institute of Drug Safety & Risk Management. 2014:1-6.
25 Kim JS, Yoon SH. Effect of Naesosan gastric motility between normal intact and antral dilatated rats. J Korean Orient Int Med. 2008;29(1):117-129.
26 Korean Diabetes Association. Treatment Guideline for Diabetes. 2018;13,17.
27 Lee MJ, Kim SS. Management of Obesity in Patients with Diabetes Mellitus. J Korean Diabetes, 2017;18:229-38,   DOI
28 Han HJ, Kim HJ, Park EY, Jang JA, An TH, Seo HS , et al. The effect of oriental obesity therapy on Morbid obese patient with Type 2 Diabetes : Two Cases Report. J Korean Med. 2010;10:57-63.
29 Wing RR, Marcus MD, Epstein LH, Jawad A. A "family-based" approach to the treatment of of obese Type II diabetic patients. J Consult Clin Psychol. 1991;59:156-62.   DOI
30 Korean Diabetes Association. Diabetes Fact Sheet. 2018.
31 Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.   DOI
32 Kim HJ, Kim KS. Improvement of type 2 diabetes by very-low-calorie diet-A case report. J Korean Med. 2002;2(1):97-102.
33 O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426-36.   DOI
34 Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022-9.   DOI
35 Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA. 2015;314:687-99.   DOI
36 Cha YY. A case Study on the Treatment of Obese patient with diabetes. J Korean Med. 2004;4(1):193-9.
37 World Health Organization-Uppsala Monitoring Centre (WHO-UMC). Causality categories [Internet]. Uppsala (Sweden): World Health Organization-Uppsala Monitoring Centre (WHO-UMC); 2018. [cited 2012 Oct 22]. Available from: https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf.
38 Korea Institute of Drug Safety & Risk Management. Adverse Drug Reaction Assessment Report. 1st ed. Seoul : Korea Institute of Drug Safety & Risk Management. 2013:60-3.
39 Korean Obesity Association. Treatment Guideline for Obesity.2018;17-18.